Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment
Ann Oncol. 2016;27(7): 1311-6; Pouessel D, Neuzillet Y, Mertens LS, van der Heijden MS, de Jong J, Sanders J, Peters D, Leroy K, Manceau A, Maille P, Soyeux P, Moktefi A, Semprez F, Vordos D, de la Taille A, Hurst CD, Tomlinson DC, Harnden P, Bostrom PJ, Mirtti T, Horenblas S, Loriot Y, Houédé N, Chevreau C, Beuzeboc P, Shariat SF, Sagalowsky AI, Ashfaq R, Burger M, Jewett MA, Zlotta AR, Broeks A, Bapat B, Knowles MA, Lotan Y, van der Kwast TH, Culine S, Allory Y, van Rhijn BW
Expression of the p53 Inhibitors MDM2 and MDM4 as Outcome Predictor in Muscle-invasive Bladder Cancer
Anticancer Res. 2016;36(10): 5205-5213; Kriegmair MC, Balk M, Wirtz R, Steidler A, Weis CA, Breyer J, Hartmann A, Bolenz C, Erben P
Prediction of cancer-specific survival after radical cystectomy in pT4a urothelial carcinoma of the bladder: development of a tool for clinical decision-making
BJU Int. 2016;117(2): 272-9; Aziz A, Shariat SF, Roghmann F, Brookman-May S, Stief CG, Rink M, Chun FK, Fisch M, Novotny V, Froehner M, Wirth MP, Schnabel MJ, Fritsche HM, Burger M, Pycha A, Brisuda A, Babjuk M, Vallo S, Haferkamp A, Roigas J, Noldus J, Stredele R, Volkmer B, Bastian PJ, Xylinas E, May M
Robotic Prostatectomy on the Web: A Cross-Sectional Qualitative Assessment
Clin Genitourin Cancer. 2016;14(4): e355-62; Borgmann H, Mager R, Salem J, Bründl J, Kunath F, Thomas C, Haferkamp A, Tsaur I
Impact of Perioperative Allogenic Blood Transfusion on Survival After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma
Clin Genitourin Cancer. 2016;14(1): 96-104; Rink M, Soave A, Dahlem R, Aziz A, Al-Sayed F, Peine S, Engel O, Kluth LA, Stenzl A, Burger M, Shariat SF, Fisch M, Fritsche HM, Gakis G
Critical analysis of a simplified Fuhrman grading scheme for prediction of cancer specific mortality in patients with clear cell renal cell carcinoma--Impact on prognosis
Eur J Surg Oncol. 2016;42(3): 419-25; Becker A, Hickmann D, Hansen J, Meyer C, Rink M, Schmid M, Eichelberg C, Strini K, Chromecki T, Jesche J, Regier M, Randazzo M, Tilki D, Ahyai S, Dahlem R, Fisch M, Zigeuner R, Chun FK
Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel
Eur Urol. 2016;70(6): 1052-1068; Seisen T, Peyronnet B, Dominguez-Escrig JL, Bruins HM, Yuan CY, Babjuk M, Böhle A, Burger M, Compérat EM, Cowan NC, Kaasinen E, Palou J, van Rhijn BW, Sylvester RJ, Zigeuner R, Shariat SF, Rouprêt M
Training, Research, and Working Conditions for Urology Residents in Germany: A Contemporary Survey
Eur Urol Focus. 2016; Borgmann H, Arnold HK, Meyer CP, Bründl J, König J, Nestler T, Ruf C, Struck J, Salem J
The Perioperative Management of Metabolically Active Tumors
Eur Urol Focus. 2016;1(3): 258-260; Mayr R, Pycha A, Burger M
Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Competing Risks Analysis
Eur Urol Focus. 2016; Vetterlein MW, Seisen T, May M, Nuhn P, Gierth M, Mayr R, Fritsche HM, Burger M, Novotny V, Froehner M, Wirth MP, Protzel C, Hakenberg OW, Roghmann F, Palisaar RJ, Noldus J, Pycha A, Bastian PJ, Trinh QD, Xylinas E, Shariat SF, Rink M, Chun FK, Dahlem R, Fisch M, Aziz A, PROMETRICS 2011 Study Group
TERT Core Promotor Mutations in Early-Onset Bladder Cancer
J Cancer. 2016;7(8): 915-20; Giedl J, Rogler A, Wild A, Riener MO, Filbeck T, Burger M, Rümmele P, Hurst C, Knowles M, Hartmann A, Zinnall U, Stoehr R
Oncologic Outcomes of Kidney Sparing Surgery versus Radical Nephroureterectomy for the Elective Treatment of Clinically Organ Confined Upper Tract Urothelial Carcinoma of the Distal Ureter
J Urol. 2016;195(5): 1354-61; Seisen T, Nison L, Remzi M, Klatte T, Mathieu R, Lucca I, Bozzini G, Capitanio U, Novara G, Cussenot O, Compérat E, Renard-Penna R, Peyronnet B, Merseburger AS, Fritsche HM, Hora M, Shariat SF, Colin P, Rouprêt M
Maintenance monotherapy with Gemcitabine following cisplatin-based primary combination chemotherapy in surgically treated advanced urothelial carcinoma: A matched-pair single institution analysis
Mol Clin Oncol. 2016;4(4): 636-642; Kalogirou C, Svistunov A, Krebs M, Lausenmeyer EM, Vergho D, Riedmiller H, Kocot A
Bladder cancer: Low adherence to guidelines in non-muscle-invasive disease
Nat Rev Urol. 2016;13(10): 570-1; van Rhijn BW, Burger M
Homozygous G/G variant of SNP309 in the human MDM2 gene is associated with earlier tumor onset in Caucasian female renal cell carcinoma patients
Oncogenesis. 2016;5: e205; Stoehr CG, Stoehr R, Wenners A, Hartmann A, Bertz S, Spath V, Walter B, Junker K, Moch H, Hinze R, Denzinger S, Bond EE, Bond GL, Bluemke K, Weigelt K, Lieb V, Nolte E, Fornara P, Wullich B, Taubert H, Wach S
Online Discussion on #KidneyStones: A Longitudinal Assessment of Activity, Users and Content
PLoS ONE. 2016;11(8): e0160863; Salem J, Borgmann H, Bultitude M, Fritsche HM, Haferkamp A, Heidenreich A, Miernik A, Neisius A, Knoll T, Thomas C, Tsaur I
The Microphthalmia-Associated Transcription Factor p.E318K Mutation Does Not Play a Major Role in Sporadic Renal Cell Tumors from Caucasian Patients
Pathobiology. 2016;83(4): 165-9; Stoehr CG, Walter B, Denzinger S, Ghiorzo P, Sturm RA, Hinze R, Moch H, Junker K, Hartmann A, Stoehr R
Immunotherapy in urothelial carcinoma: fade or future standard?
Transl Androl Urol. 2016;5(5): 662-667; Breyer J, Burger M, Otto W
Downregulation of Checkpoint Protein Kinase 2 in the Urothelium of Healthy Male Tobacco Smokers
Urol Int. 2016;97(4): 480-481; Breyer J, Denzinger S, Hartmann A, Otto W
Oncological Outcomes of Patients with Concomitant Bladder and Urethral Carcinoma
Urol Int. 2016;97(2): 134-41; Gakis G, Efstathiou JA, Daneshmand S, Keegan KA, Clayman RH, Hrbacek J, Ali-El-Dein B, Zaid HB, Schubert T, Mischinger J, Todenhöfer T, Galland S, Olugbade K, Rink M, Fritsche HM, Burger M, Chang SS, Babjuk M, Thalmann GN, Stenzl A, Morgan TM
Prognostic Significance of Incidental Prostate Cancer at Radical Cystoprostatectomy for Bladder Cancer
Urol Int. 2016;97(1): 42-8; Gakis G, Rink M, Fritsche HM, Graefen M, Schubert T, Hassan F, Chun FK, Brummeisl W, Fisch M, Burger M, Stenzl A, Renninger M
Prediction of Locally Advanced Urothelial Carcinoma of the Bladder Using Clinical Parameters before Radical Cystectomy--A Prospective Multicenter Study
Urol Int. 2016;96(1): 57-64; Martini T, Aziz A, Roghmann F, Rink M, Chun FK, Fisch M, Trojan L, Hakenberg OW, Zastrow S, Wirth MP, Moersdorf J, Brookman-May S, Stief CG, Haferkamp A, Wagenlehner F, Hohenfellner M, Herrmann E, Lusuardi L, Grimm MO, Müller SC, Roigas J, Bastian PJ, Gierth M, Burger M, Pycha A, Seitz C, May M, Bolenz C
Comparative analysis of the effect of prostatic invasion patterns on cancer-specific mortality after radical cystectomy in pT4a urothelial carcinoma of the bladder
Urol Oncol. 2016;34(10): 432.e1-8; Vallo S, Gilfrich C, Burger M, Volkmer B, Boehm K, Rink M, Chun FK, Roghmann F, Novotny V, Mani J, Brisuda A, Mayr R, Stredele R, Noldus J, Schnabel M, May M, Fritsche HM, Pycha A, Martini T, Wirth M, Roigas J, Bastian PJ, Nuhn P, Dahlem R, Haferkamp A, Fisch M, Aziz A
Prerequisites, skills and productivity of young academic urologists in Germany
Urologe A. 2016; Borgmann H, Bründl J, Huber J, Ruf C, Schagdarsurgengin U, Wullich B, Salem J
Bladder-sparing therapy as an alternative to cystectomy : Commentary on organ-sparing therapy in bladder cancer
Urologe A. 2016;55(5): 615; Burger M
Effects of modified inclusion criteria and negative reporting about PSA screening on the number of potentially recruitable patients for the PREFERE study
Urologe A. 2016;55(9): 1213-7; Mathes J, Burger M, Gschwend JE, Hakenberg OW, Krege S, Lehmann J, Miller K, Roigas J, Roth S, Kälble T
What do prostate cancer patients know about smoking? : Results of a bicentric questionnaire study (KRAUT study)
Urologe A. 2016;55(8): 1078-85; May M, Gilfrich C, Spachmann P, Maurer O, Dombrowski MK, Fritsche HM, Wöhr M, Brookman-May S, Karl T, Schostak M, Burger M, Lebentrau S
Regional for Residents. GeSRU Programs at Regional Urology Meetings in Germany
Urologe A. 2016;55(4): 532-3, Paffenholz P, Borgmann H, Nachite-Berges S, Borowitz R, Bründl J, Boehm K, Probst K, Schneidewind L, Schmid M, Salem J
Residents training in private practice : Conflicts between circumstances, willingness, and reality
Urologe A. 2016;55(8): 1062-70; Salem J, Borgmann H, Bründl J, Lausenmeyer EM, Lent V, Schroeder A, Heidenreich A
Antibiotic stewardship (ABS). Definition, contents, necessity and practice on examples of current clinical-urological controversies
Urologe A. 2016;55(4): 489-93; Schneidewind L, Kranz J, Boehm K, Spachmann P, Siegel F, Huck N, Fritsche HM
ESR1, ERBB2, and Ki67 mRNA expression predicts stage and grade of non-muscle-invasive bladder carcinoma (NMIBC)
Virchows Arch. 2016;469(5): 547-552; Breyer J, Wirtz RM, Laible M, Schlombs K, Erben P, Kriegmair MC, Stoehr R, Eidt S, Denzinger S, Burger M, Hartmann A, Otto W
The German linguistic validation of the Ureteral Stent Symptoms Questionnaire (USSQ)
World J Urol. 2016; Abt D, Dötzer K, Honek P, Müller K, Engeler DS, Burger M, Schmid HP, Knoll T, Sanguedolce F, Joshi HB, Fritsche HM
Epithelial-mesenchymal transformation markers E-cadherin and survivin predict progression of stage pTa urothelial bladder carcinoma
World J Urol. 2016;34(5): 709-16;Breyer J, Gierth M, Shalekenov S, Aziz A, Schäfer J, Burger M, Denzinger S, Hofstädter F, Giedl C, Otto W
Prognostic factors and outcomes in primary urethral cancer: results from the international collaboration on primary urethral carcinoma
World J Urol. 2016;34(1): 97-103; Gakis G, Morgan TM, Efstathiou JA, Keegan KA, Mischinger J, Todenhoefer T, Schubert T, Zaid HB, Hrbacek J, Ali-El-Dein B, Clayman RH, Galland S, Olugbade K, Rink M, Fritsche HM, Burger M, Chang SS, Babjuk M, Thalmann GN, Stenzl A, Daneshmand S
Kontakt
Terminvereinbarung und
Befundanforderungen:
E-Mail uro-ambulanz(at)csj.de
Telefon 0941 782-3511
Fax 0941 782-3545
Sekretariat:
E-Mail urologie(at)csj.de
Telefon 0941 782-3510
Fax 0941 782-3515
